Q32 Total Current Assets vs Accounts Payable Analysis
| QTTB Stock | 24.55 2.49 9.21% |
Q32 Bio financial indicator trend analysis is much more than just breaking down Q32 Bio prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Q32 Bio is a good investment. Please check the relationship between Q32 Bio Total Current Assets and its Accounts Payable accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Q32 Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.
Total Current Assets vs Accounts Payable
Total Current Assets vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Q32 Bio Total Current Assets account and Accounts Payable. At this time, the significance of the direction appears to have strong relationship.
The correlation between Q32 Bio's Total Current Assets and Accounts Payable is 0.64. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Q32 Bio, assuming nothing else is changed. The correlation between historical values of Q32 Bio's Total Current Assets and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Q32 Bio are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Current Assets i.e., Q32 Bio's Total Current Assets and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.64 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Accounts Payable
An accounting item on the balance sheet that represents Q32 Bio obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Q32 Bio are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from Q32 Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Q32 Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Q32 Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.At present, Q32 Bio's Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.03, whereas Tax Provision is forecasted to decline to about 53 K.
| 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 45.9M | 92.7M | 69.8M | Cost Of Revenue | 2.6M | 578K | 549.1K |
Q32 Bio fundamental ratios Correlations
Click cells to compare fundamentals
Q32 Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Q32 Bio fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 310.6M | 263.7M | 35.2M | 61.8M | 306.1M | 190.9M | |
| Other Current Liab | 9.0M | 9.8M | 4.5M | 8.5M | 7.0M | 7.3M | |
| Total Current Liabilities | 12.4M | 22.7M | 7.2M | 57.9M | 11.6M | 20.5M | |
| Total Stockholder Equity | 258.5M | 196.0M | (89.2M) | (130.7M) | 73.0M | 61.0M | |
| Property Plant And Equipment Net | 42.7M | 42.9M | 203K | 9.2M | 650K | 617.5K | |
| Net Debt | (53.8M) | (202.0M) | (27.3M) | 838K | (37.9M) | (39.8M) | |
| Retained Earnings | (199.7M) | (328.4M) | (90.5M) | (133.3M) | (542.1M) | (515.0M) | |
| Accounts Payable | 2.6M | 4.7M | 2.7M | 1.4M | 3.2M | 3.4M | |
| Cash | 53.8M | 217.4M | 32.2M | 43.9M | 39.3M | 67.1M | |
| Non Current Assets Total | 44.0M | 44.2M | 1.2M | 14.9M | 222.2M | 233.3M | |
| Cash And Short Term Investments | 262.4M | 217.4M | 32.2M | 43.9M | 82.7M | 99.4M | |
| Common Stock Shares Outstanding | 2.3M | 2.6M | 3.1M | 3.2M | 3.2M | 2.8M | |
| Liabilities And Stockholders Equity | 310.6M | 263.7M | 35.2M | 61.8M | 306.1M | 190.9M | |
| Non Current Liabilities Total | 39.7M | 45.1M | 117.1M | 134.6M | 221.6M | 232.6M | |
| Other Current Assets | 3.8M | 1.7M | 842K | 1.9M | 1.3M | 1.8M | |
| Other Stockholder Equity | 458.0M | 524.4M | 1.3B | 1.3B | 615.1M | 620.3M | |
| Total Liab | 52.1M | 67.7M | 124.4M | 192.5M | 233.1M | 244.8M | |
| Total Current Assets | 266.6M | 219.6M | 34.0M | 46.9M | 83.9M | 101.6M | |
| Accumulated Other Comprehensive Income | (77K) | 183K | (7K) | (404K) | (5K) | (5.3K) | |
| Common Stock | 3K | 4K | 5K | 1K | 6K | 3.1K | |
| Current Deferred Revenue | 809K | 5.6M | 3.2M | 14.5M | 16.7M | 17.5M | |
| Short Term Investments | 176.5M | 208.6M | 47.5M | 141.0M | 43.4M | 41.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Q32 Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Q32 Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Q32 Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Q32 Bio Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Q32 Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Q32 Bio. If investors know Q32 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Q32 Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.50) | Revenue Per Share (1.24) |
The market value of Q32 Bio is measured differently than its book value, which is the value of Q32 that is recorded on the company's balance sheet. Investors also form their own opinion of Q32 Bio's value that differs from its market value or its book value, called intrinsic value, which is Q32 Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Q32 Bio's market value can be influenced by many factors that don't directly affect Q32 Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Q32 Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Q32 Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Q32 Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.